Vaccination with a Nogo-A-derived peptide after incomplete spinal-cord injury promotes recovery via a T-cell-mediated neuroprotective response: Comparison with other myelin antigens

PNAS, 2001 · DOI: 10.1073/pnas.011585298 · Published: December 18, 2001

Simple Explanation

The study investigates whether immunization with a peptide derived from Nogo-A, a protein that inhibits nerve regeneration, can promote recovery after spinal cord injury. The findings suggest that immunization with a Nogo-A derived peptide after spinal cord injury can reduce neuronal degeneration and promote recovery. The protective effect appears to be mediated by T cells, a type of immune cell, rather than antibodies.

Study Duration

Not specified

Participants

Inbred adult Sprague–Dawley (SPD) and Lewis rats (10–12 weeks old, 200–250 g)

Evidence Level

Not specified

Key Findings

1
Posttraumatic immunization with p472, a peptide derived from Nogo-A, substantially reduced neuronal degeneration and promoted recovery after incomplete spinal-cord contusion in rats.
2
The observed effect seemed to be mediated by T cells and could be reproduced by passive transfer of a T cell line directed against the Nogo-A peptide.
3
Immunization with p472 reduces loss of retinal ganglion cells (RGCs) after optic-nerve injury.

Research Summary

This study investigates the effect of posttraumatic immunization with a peptide derived from Nogo-A (p472) on recovery from spinal cord injury in rats. The study found that immunization with p472 reduced neuronal degeneration and promoted recovery. The neuroprotective effect of p472 was mediated by T cells, as demonstrated by passive transfer experiments. The study compared the effects of p472 with an MBP-derived peptide (Ala-91) and found that both peptides were effective. The study also showed that immunization with p472 reduced the loss of retinal ganglion cells after optic nerve injury. The findings suggest that T cell-mediated active or passive vaccination is a promising treatment for posttraumatic treatment of the injured spinal cord.

Practical Implications

Therapeutic Potential

T cell-mediated active or passive vaccination could be a promising treatment for spinal cord injuries.

Understanding Immune Response

The study highlights the beneficial role of T cell-mediated autoimmune responses in promoting recovery after CNS injuries.

Peptide Selection

Careful selection of myelin-associated peptides for therapy is crucial to avoid autoimmune diseases or interference with essential physiological activities.

Study Limitations

1
The study was conducted on rats, and the results may not be directly applicable to humans.
2
The exact mechanisms underlying the neuroprotective effect of T cells need further investigation.
3
The potential for long-term side effects of immunization with Nogo-A-derived peptides, such as delayed antibody responses, was not fully explored.

Your Feedback

Was this summary helpful?

Back to Spinal Cord Injury